EP0368904A1 - Purification of gm-csf - Google Patents

Purification of gm-csf

Info

Publication number
EP0368904A1
EP0368904A1 EP88906521A EP88906521A EP0368904A1 EP 0368904 A1 EP0368904 A1 EP 0368904A1 EP 88906521 A EP88906521 A EP 88906521A EP 88906521 A EP88906521 A EP 88906521A EP 0368904 A1 EP0368904 A1 EP 0368904A1
Authority
EP
European Patent Office
Prior art keywords
csf
column
removal
chromatography
dye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP88906521A
Other languages
German (de)
French (fr)
Inventor
Paul P. Trotta
Gail F. Seelig
Robert A. Kosecki
Paul Reichert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0368904A1 publication Critical patent/EP0368904A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Definitions

  • the present invention relates to a method for purifying granulocyte-macrophage colony-stimulating factor (GM-CSF), particularly human GM-CSF.
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • the method of this invention provides for a particular series of purification steps which result in GM-CSF with high specific biological activity, high electrophoretic purity and a low level of pyrogens or other contaminants.
  • Circulating blood cells are constantly replaced by newly developed cells.
  • Replacement blood-cells are formed in a process termed hematopoiesis , in which at least eight mature blood cell lineages are produced: red blood cells (erythrocytes), macrophages (monocytes), eosinophilic granulocytes, megakaryocytes (platelets), neutrophilic granulocytes, basophilic granulocytes (mast cells), T lymphocytes, and B lymphocytes [see Burgess and Nicola, Growth Factors and Stem Cells (Acc.dem.ic Press, New York, 1983)].
  • CSFs colony stimulating factors
  • glycoproteins are so named because of the in vivo and in vitro assays used to detect their presence.
  • Techniques for the clonal culture of hematopoietic cells in semisolid culture medium have been especially important in the development of in vitro assays.
  • individual progenitor cells i.e., cells developmentally committed to a particular -lineage, but still capable of proliferation
  • GM-CSF Complementary DNAs
  • cDNAs Complementary DNAs
  • GM-CSF Complementary DNAs
  • cDNAs Complementary DNAs
  • GM-CSF Complementary DNAs
  • non-recombinant GM-CSF has been purified from culture supernatants of the Mo cell line (described in U.S. Patent 4,438,032), and the first sixteen amino acids from the N-terminus have been sequenced [Gasson et al. , Science, Vol. 226, pgs. 1339- 1342 (1984)].
  • heterogeneity of the nucleotide sequence and amino acid sequence has been observed. For example, at the amino acid level both threonine and isoleucine have been observed at position 100 with respect to the N-terminal alanine, suggesting that several allelic forms, or polymorphs, of GM-CSF may exist within human populations.
  • total mRNA is extracted from cells (e.g., a nontransformed human T cell source) producing polypeptides exhibiting the desired activity.
  • the double-stranded cDNAs can be constructed from this total mRNA by using primer-initiated reverse transcrip ⁇ tion to make first the complement of each mRNA sequence, and then by priming for second strand synthesis. Subsequently, the cDNAs can be cloned by joining them to suitable plasmids or bacteriophage vectors through complementary homopolymeric tails or cohesive ends created with linker segments containing appropriate restriction sites, and then transforming a suitable host.
  • a wide range of expression systems i.e., host/ expression-vector combinations
  • host/expression-vector combinations can be used to produce the proteins purified by the process of this invention.
  • Possible types of host cells include, but are not limited to, bacterial, yeast, insect, mammalian and the like.
  • the present invention comprises a unique series of chromatographic steps which purify GM-CSF to more than 55% homogeneity, with the retention of biological activity, and in good yield.
  • the procedure is composed of sequential anion- exchange, dye-ligand affinity, gel filtration and reversed-phase chromatography.
  • the anion exchange column is used to remove proteases from the supernatant obtained after the host cells are killed and filtered off.
  • Quaternary aminoethyl, mixed a ine or other intermediate base resins or weak base resins such as p-amino benzyl cellulose are particularly useful.
  • Quaternary aminoethyl is a preferred anion exchange resin.
  • the quaternary aminoethyl may be attached to a cross-linked dextran, cellulose, agarose or acrylic support.
  • the dye-ligand affinity column is used to remove hydrophobic impurities.
  • a typical column comprises a triazinyl dye such as Procion Red HE-3B on an agarose support (e.g., Matrex Gel Red A, manufactured by Amicon Corp., Scientific Systems Division, Danvers, MA).
  • Gel filtration is used to separate high and low molecular weight impurities.
  • a particularly useful filtration gel is a cross-linked dextran-based gel, identified by the trademark SEPHADEX G-100, manufactured by Pharmacia Fine Chemicals (Piscataway, N.J.).
  • SEPHADEX G-100 cross-linked dextran-based gel
  • the resin has a fractionation molecular weight range of 4,000 to 150,000 for globular proteins and peptides and 1,000 to 100,000 polysaccha ides.
  • Other commercially available resins having cut-off ranges of from about 1,000 to about 200,000 for proteins may also be used.
  • Reversed phase chromatography e.g. fast protein liquid chromatography (FPLC) and high pressure liquid chromatography (HPLC) has been found to be the only procedure capable of removing GM-CSF-related proteins identifiable on electrophoresis with no apparent denaturation of GM-CSF.
  • Any C4 or C8 column may .be used, for example, PRORPC-C8 (manufactured by Pharmacia) for •FPLC and Dynamax-C4 or Dynamax-C8 (manufactured by Rainin Instruments Co., oburn, MA) for HPLC.
  • the present invention relates to the purification of proteins having the sequence of the cDNA insert of clone pcD-human-GM-CSF illustrated below, which has been deposited with the American Type Culture Collection, Rockville, Maryland, under accession number 39923.
  • Protein concentration is determined * at each stage by a Coomassie blue binding assay . pH measurements may vary by _+_ 0.2 pH units and conductivity measurements may vary by _+_ 3 mS . If the expected degree of purification is not achieved in any chromatographic procedure , eluted fractions may be re chroma tographed on the same type of column or, alternatively, recycled through, a previous step or a previous series of steps . An ammonium sulfate precipitation and/or ultraf iltration step may be performed to concentrate and/or store the protein, as e.g. in Stage III below .
  • Cells are killed, for example by adjusting to •pH 2.0 (or less) by sequential additions of suitable acids, e.g. by adding 85% phosphoric acid to pH 4.5 and 50% trichloroacetic acid to pH 2.0. Substantially all of the suspension liquid is removed from the cells and discarded, a second suspension of the treated cells is prepared, said second suspension is neutralized, and the GM-CSF-containing liquid is separated from the suspended cells, e.g. by filtration through a 0.2 ⁇ membrane. The conductivity of the extract is then adjusted to 15-20 mS by addition of water. A low conductivity is required to minimize the amount of dilution required to allow GM-CSF to bind to the QAE column.
  • suitable acids e.g. by adding 85% phosphoric acid to pH 4.5 and 50% trichloroacetic acid to pH 2.0.
  • a second suspension of the treated cells is prepared, said second suspension is neutralized, and the GM-CSF-containing liquid is separated from the suspended cells, e
  • the neutralized extract is adjusted to pH 7.5 with sodium hydroxide or hydrochloric acid, as appropriate.
  • the conductivity of the neutralized extract is adjusted to 5-10 mS by addition of deionized water.
  • the QAE column or other suitable anion exchange column is equilibrated with at least 2-3 column volumes of suitable pH 7.5 buffer, e.g. 20 mM Tris-HCl.
  • the extract containing GM-CSF is applied to the column at a loading of not greater than 20 mg per ml of resin.
  • the column is eluted with 10-20 column volumes of a gradient of sodium chloride in the range of 0-0.5 M dissolved in the same buffer in which the column was equilibrated.
  • the combined fractions from the anion exchange (e.g. QAE) column are diluted with deionized water to a conductivity of 5-10 mS and loaded onto a dye-ligand affinity column, e.g. Procion Red HE3B attached to an agarose support, which had been previously equilibrated with 2-3 column volumes of appropriate pH 7.5 buffer, e.g. 20 mM Tris-HCl.
  • the amount of protein loaded onto the column should not exceed 10 mg per ml of gel.
  • the column is washed with 3-4 column volumes of the equilibration buffer. Elution is performed with between 5 and 15 volumes of a gradient of sodium chloride or other appropriate salt from 0 to 0.75 M dissolved in the equilibration buffer.
  • the fractions to be employed in Stage IV are combined on the basis of SDS-PAGE.
  • the solution is concentrated by ultrafiltration employing a 3,000-5,000 molecular weight cut-off membrane.
  • the final protein concentration should be 1.0 mg/ml or greater.
  • Ammonium sulfate is added to a final concentration of 60-70%.
  • the precipitate is collected by centrifugation and then washed once with 20 mM Tris-HCl, pH 7.5, or other suitable buffer containing the same concentration of ammonium sulfate as employed for precipitation. The precipitate is collected by centrifugation and dissolved in the same buffer.
  • Stage V Gel Filtration Chromatography
  • the redissolved ammonium sulfate precipitate may be clarified by centrifugation, if required.
  • the solution is filtered through a 0.2 u filter and charged onto a gel filtration column such as a Sephadex G-100 column equilibrated with an appropriate buffer at pH 7.5, e.g. 20 mM Tris-HCl.
  • the amount of protein loaded onto the column should not exceed 3 mg per ml of gel.
  • the column is eluted with the same buffer. Fractions for stage VI are combined based on SDS-PAGE.
  • the combined fractions from the gel filtration are passed through a 0.2 ⁇ filter and applied to a reversed-phase column, e.g., FPLC or HPLC columns.
  • a reversed-phase column e.g., FPLC or HPLC columns.
  • the column is equilibrated with an acidic solution such as 0.1% trifluoroacetic acid (TFA) and elution is performed with a gradient of 0-100% of an inert solvent such as acetonitrile dissolved in the acidic solution.
  • Fractions are combined based on SDS-PAGE.
  • the solution is lyophilized and the dried powder is dissolved in a buffer solution at pH 7.2, e.g., 20 mM sodium phosphate.
  • the solution from Stage VI is dialyzed against a buffer at pH 7.2, e.g., 20 mM sodium phosphate. Two changes of buffer are performed with a minimum of 4-5 hours between changes. If required, the dialyzed solution is concentrated by ultrafiltration using a 3,000-5,000 molecular weight cut-off membrane to a protein concentration of at least 1.0 mg/ml.
  • the solution of purified GM-CSF is passed through a 0.2 ⁇ filter and stored frozen at about -20°C or below. Following is a specific example of GM-CSF purification. Roman numerals correspond to some of the Stages of the general description above.
  • the neutralized protein extract was adjusted to pH 7.5 with sodium hydroxide. The extract was then diluted approximately 2-fold with cold deionized water to reach a final conductivity of 8 S.
  • a 6.5 liter column (BIOPROCESS 252/15, manufactured by Pharmacia) was equilibrated with 3 column volumes of 20 mM Tris.HCl, pH 7.5. Extract (50 liters) was applied to the column at a loading of 8.6 mg protein per ml of resin.
  • the column was eluted at a flow of 400 ml/ in, first with 30 liters of equilibration buffer, and then with 70 liters of a linear gradient established between 35 liters of 20 mM Tris.HCl, pH 7.5 and 35 liters of 20 mM Tris.HCl, pH 7.5 containing 0.4 M NaCl. Fractions (4-5 liters) were combined based on gel electrophoresis (SDS-PAGE) and the pooled protein (2.0 grams) was chromatographed in Stage III.
  • the combined fractions from the QAE column were concentrated by ultrafiltration (3,000-5,000 molecular weight cut-off membrane) to 1 liter, and then diluted 5- fold with cold deionized water to a conductivity of 8 mS.
  • This pool (5 liters) was then loaded at a ratio of 6.7 mg/ml onto a 300 ml Matrex Gel Red A column which had previously been equilibrated with three column volumes of 20 mM Tris.HCl, pH 7.5.
  • the column was then washed with 600 ml of equilibrating buffer, and the 2.0 gram load was eluted using a linear gradient established between 1.5 liters of 20 mM Tris.HCl, pH 7.5 and 1.5 liters of 20 mM Tris.HCl, pH 7.5 containing 0.75 M NaCl.
  • the fractions were combined based on gel electrophoresis, and the fractions (1.5 liters containing 1.12 gram of protein) were concentrated by ultrafiltration in Stage IV.
  • the 1.5 liter eluate of the dye ligand chromatography contained 0.75 mg/ml. Ultrafiltration of this pool was performed in an Amicon high-output stainless steel stirred cell (Model 2000). A YM-5 membrane (150 mm) (Amicon) was used with a flow rate of 10 ml/min., 80 PSI and 4°C. The sample was concentrated to a volume of 75 ml and 10-15 mg/ml. Following the ultrafiltration, the sample was filtered through a .22 ⁇ cellulose nitrate membrane. Ammonium sulfate was added to a final concentration of 60% (390 mg/ml).
  • the solution was held at 4°C without mixing for 2 hours, and then centrifuged at 4,000 rpm for 45 min at 4°C.
  • the precipitate was collected, and resuspended in one liter of 20 mM Tris.HCl, pH 7.5 containing 60% saturated ammonium sulfate at 4°C.
  • the sample was centrifuged at 4,000 rpm for 45 min at 4°C.
  • the redissolved ammonium sulfate pellet was charged onto a 2 liter column at a flow rate of 2 ml/min. A loading ratio of 0.5 mg of protein per ml of resin was used and the sample was eluted with the equilibrating buffer, 20 mM Tris.HCl, pH 7.5. Fractions were combined based on gel electrophoresis (SDS-PAGE), and the 300 ml volume containing 350 mg of protein was frozen at -20°C until it was applied to the reversed- phase column. Stage VI. Reversed-Phase Column Chromatography
  • the combined fractions of the gel filtration column were passed through a 0.2 ⁇ filter and applied onto a 20 ml PRORPC-C2/C8 (Pharmacia) column at a flow rate of 2.5 ml/min.
  • the column had previously been equilibrated with solvent containing 0.1% TFA in water.
  • Four identical chromatographies (100 mg per run) were performed. Sample was eluted using a linear gradient between 35% acetonitrile, 0.1% TFA and 100% acetonitrile, 0.1% TFA over a 125 min. time period. Fractions were combined based on SDS-PAGE. The solution was lyophilized, and the dried powder was dissolved in 20 mM sodium phosphate, pH 7.2.
  • the pool from the reversed-phase column was dialysed against three changes of 20 mM sodium phosphate buffer, pH 7.2. The solution was then sterile-filtered through a 0.2 ⁇ filter and frozen at -20°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
  • Amplifiers (AREA)

Abstract

A method of purifying granulocyte-macrophage colony-stimulating factor (GM-CSF), particularly recombinant human GM-CSF, in good yield and with retention of biological activity, comprising sequential anion-exchange, dye-ligand affinity, gel filtration and reversed-phase chromatography is disclosed.

Description

PURIFICATION OF GM-CSF
SUMMARY OF THE INVENTION
The present invention relates to a method for purifying granulocyte-macrophage colony-stimulating factor (GM-CSF), particularly human GM-CSF.
The detection, isolation and purification of these factors is extremely difficult, for it is frequently complicated by the nature of the supernatants in which they are typically located, the divergencies and cross-overs of activities of the various components in the mixtures, the sensitivity (or lack thereof) of the assays utilized to ascertain the factors' properties, the frequent similarity in the range of molecular weights and other characteristics of the factors, and the very low concentration of the factors in their natural settings.
The method of this invention provides for a particular series of purification steps which result in GM-CSF with high specific biological activity, high electrophoretic purity and a low level of pyrogens or other contaminants.
BACKGROUND Circulating blood cells are constantly replaced by newly developed cells. Replacement blood-cells are formed in a process termed hematopoiesis , in which at least eight mature blood cell lineages are produced: red blood cells (erythrocytes), macrophages (monocytes), eosinophilic granulocytes, megakaryocytes (platelets), neutrophilic granulocytes, basophilic granulocytes (mast cells), T lymphocytes, and B lymphocytes [see Burgess and Nicola, Growth Factors and Stem Cells (Acc.dem.ic Press, New York, 1983)]. Much of the control of blood cell formation is mediated by a group of interacting glycoproteins termed colony stimulating factors (CSFs). These glycoproteins are so named because of the in vivo and in vitro assays used to detect their presence. Techniques for the clonal culture of hematopoietic cells in semisolid culture medium have been especially important in the development of in vitro assays. In such cultures, individual progenitor cells (i.e., cells developmentally committed to a particular -lineage, but still capable of proliferation) are able to proliferate to form a "colony of maturing progeny in a manner which is believed to be essentially identical to the comparable process in vivo.
As more CSFs become available, primarily through molecular cloning, interest has heightened in finding clinical applications for them. Their use has been suggested for several clinical situations where the stimulation of blood cell generation would be desirable, such as for rehabilitative therapy after chemotherapy or radiation therapy of tumors, treatment of myeloid hypoplasias, treatment of neutrophil deficiency, treatment to enhance hematopoietic regeneration following bone marrow transplantation, and treatment to increase - host resistance to established infections.
Complementary DNAs (cDNAs) for GM-CSF, factors which support growth and development of granulocytes and macrophages, have recently been cloned and sequenced by a number of laboratories. Moreover, non-recombinant GM-CSF has been purified from culture supernatants of the Mo cell line (described in U.S. Patent 4,438,032), and the first sixteen amino acids from the N-terminus have been sequenced [Gasson et al. , Science, Vol. 226, pgs. 1339- 1342 (1984)]. Among the human GM-CSFs, heterogeneity of the nucleotide sequence and amino acid sequence has been observed. For example, at the amino acid level both threonine and isoleucine have been observed at position 100 with respect to the N-terminal alanine, suggesting that several allelic forms, or polymorphs, of GM-CSF may exist within human populations.
A variety of methods are now available for de novo preparation and cloning of cDNAs, and for the construction of cDNA libraries.
By way of example, total mRNA is extracted from cells (e.g., a nontransformed human T cell source) producing polypeptides exhibiting the desired activity. The double-stranded cDNAs can be constructed from this total mRNA by using primer-initiated reverse transcrip¬ tion to make first the complement of each mRNA sequence, and then by priming for second strand synthesis. Subsequently, the cDNAs can be cloned by joining them to suitable plasmids or bacteriophage vectors through complementary homopolymeric tails or cohesive ends created with linker segments containing appropriate restriction sites, and then transforming a suitable host. A wide range of expression systems (i.e., host/ expression-vector combinations) can be used to produce the proteins purified by the process of this invention. Possible types of host cells include, but are not limited to, bacterial, yeast, insect, mammalian and the like.
Various methods have been disclosed for extracting the GM-CSF from the host cells and subsequently purifying it, but GM-CSF is not always adequately purified in good yield and with retention of biological activity.- DETAILED DESCRIPTION
The present invention comprises a unique series of chromatographic steps which purify GM-CSF to more than 55% homogeneity, with the retention of biological activity, and in good yield.
The procedure is composed of sequential anion- exchange, dye-ligand affinity, gel filtration and reversed-phase chromatography.
The anion exchange column is used to remove proteases from the supernatant obtained after the host cells are killed and filtered off. Quaternary aminoethyl, mixed a ine or other intermediate base resins or weak base resins such as p-amino benzyl cellulose are particularly useful. Quaternary aminoethyl is a preferred anion exchange resin. The quaternary aminoethyl may be attached to a cross-linked dextran, cellulose, agarose or acrylic support.
The dye-ligand affinity column is used to remove hydrophobic impurities. A typical column comprises a triazinyl dye such as Procion Red HE-3B on an agarose support (e.g., Matrex Gel Red A, manufactured by Amicon Corp., Scientific Systems Division, Danvers, MA).
Gel filtration is used to separate high and low molecular weight impurities. A particularly useful filtration gel is a cross-linked dextran-based gel, identified by the trademark SEPHADEX G-100, manufactured by Pharmacia Fine Chemicals (Piscataway, N.J.). The resin has a fractionation molecular weight range of 4,000 to 150,000 for globular proteins and peptides and 1,000 to 100,000 polysaccha ides. Other commercially available resins having cut-off ranges of from about 1,000 to about 200,000 for proteins may also be used.
Reversed phase chromatography, e.g. fast protein liquid chromatography (FPLC) and high pressure liquid chromatography (HPLC), has been found to be the only procedure capable of removing GM-CSF-related proteins identifiable on electrophoresis with no apparent denaturation of GM-CSF. Any C4 or C8 column may .be used, for example, PRORPC-C8 (manufactured by Pharmacia) for •FPLC and Dynamax-C4 or Dynamax-C8 (manufactured by Rainin Instruments Co., oburn, MA) for HPLC.
In particular the present invention relates to the purification of proteins having the sequence of the cDNA insert of clone pcD-human-GM-CSF illustrated below, which has been deposited with the American Type Culture Collection, Rockville, Maryland, under accession number 39923.
HUMAN GM-CSF
10 20 30 47
ACACAGAGAG AAAGGCTAAA GTTCTCTGGA GG ATG TGG CTG CAG AGC CTG CTG CTC TTG
MET Trp Leu Gin Ser Leu Leu Leu Leu
62 77 92 107
GGC ACT GTG GCC TGC AGC ATC TCT GCA CCC GCC CGC TCG CCC AGC CCC AGC ACG Gly Thr Val Ala Cys Ser lie Ser Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr
122 137 152 167
CAG CCC TGG GAG CAT GTG AAT GCC ATC CAG GAG GCC CGG CGT CTC CTG AAC CTG Gin Pro Trp Glu His Val Asn Ala lie Gin Glu Ala Arg Arg Leu Leu Asn Leu
182 197 212
AGT AGA GAC ACT GCT GCT GAG ATG AAT GAA ACA GTA GAA GTC ATC TCA GAA ATG Ser Arg Asp Thr Ala Ala Glu Met Asn Glu Thr Val Glu Val He Ser Glu Met
227 242 257 272
TTT GAC CTC CAG GAG CCG ACC TGC CTA CAG ACC CGC CTG GAG CTG TAC AAG CAG Phe Asp Leu Gin Glu Pro Thr Cys Leu Gin Thr Arg Leu Glu Leu Tyr Lys Gin
287 302 317
GGC CTG CGG GGC AGC CTC ACC AAG CTC AAG GGC CCC TTG ACC ATG ATG GCC AGC Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met Met Ala Ser
332 347 362 377
CAC TAC AAG CAG CAC TGC CCT CCA ACC CCG GAA ACT TCC TGT GCA ACC CAG ATT
His Tyr Lys Gin His Cys Pro Pro Thr Pro Glu Thr Ser Cys Ala Thr Gin He
392 407 422 437
ATC ACC TTT GAA AGT TTC AAA GAG AAC CTG AAG GAC TTT CTG CTT GTC ATC CCC He Thr Phe Glu Ser Phe Lys Glu Asn Leu Lys Asp Phe Leu Leu Val He Pro 452 467 477 487 497
TTT GAC TGC TGG GAG CCA GTC CAG GAG TGA GACCGGCCAG ATGAGGCTGG CCAAGCCGGG Phe Asp Cys Trp Glu Pro Val Gin Glu .
507 517 527 537 547 557
GAGCTGCTCT CTCATGAAAC AAGAGCTAGA AACTCAGGAT GGTCATCTTG GAGGGACCAA
567 577 587 597 607 617
GGGGTGGGCC ACAGCCATGG TGGGAGTGGC CAGGACCTGC CCTGGGCACA CTGACCCTGA
627 637 647 657 667 677
TACAGGCATG GCAGAAGAAT GGGAATATTT TATACTGACA GAAATCAGTA ATATTTATAT
687 697 707 * 717 727 737
ATTTATATTT TTAAAATATT TATTTATTTA TTTATTTAAG TTCATATTCC ATATTTATTC
747 757 767 777 787
AAGATGTTTT ACCGTAATAA TTATTATTAA AAATATGCTT CTAAAAAAAA
The following are general aspects of the purification protocol, which is described in more detail in seven stages below :
All operations are performed at 2-15 °C, unless otherwise indicated . Protein concentration is determined* at each stage by a Coomassie blue binding assay . pH measurements may vary by _+_ 0.2 pH units and conductivity measurements may vary by _+_ 3 mS . If the expected degree of purification is not achieved in any chromatographic procedure , eluted fractions may be re chroma tographed on the same type of column or, alternatively, recycled through, a previous step or a previous series of steps . An ammonium sulfate precipitation and/or ultraf iltration step may be performed to concentrate and/or store the protein, as e.g. in Stage III below . All solvents , including those that are employed for either equilibration or elution of columns , are f iltered prior to use through a 0.2 μ membrane . USP XIX grade water is employed in the preparation of all solvents after Stage IV below. Stage I. Cell Killing and Protein Extractions
Cells are killed, for example by adjusting to •pH 2.0 (or less) by sequential additions of suitable acids, e.g. by adding 85% phosphoric acid to pH 4.5 and 50% trichloroacetic acid to pH 2.0. Substantially all of the suspension liquid is removed from the cells and discarded, a second suspension of the treated cells is prepared, said second suspension is neutralized, and the GM-CSF-containing liquid is separated from the suspended cells, e.g. by filtration through a 0.2 μ membrane. The conductivity of the extract is then adjusted to 15-20 mS by addition of water. A low conductivity is required to minimize the amount of dilution required to allow GM-CSF to bind to the QAE column.
Stage II. Quaternary Aminoethyl (QAE) Column Chromatography
If required, the neutralized extract is adjusted to pH 7.5 with sodium hydroxide or hydrochloric acid, as appropriate. The conductivity of the neutralized extract is adjusted to 5-10 mS by addition of deionized water. The QAE column or other suitable anion exchange column is equilibrated with at least 2-3 column volumes of suitable pH 7.5 buffer, e.g. 20 mM Tris-HCl. The extract containing GM-CSF is applied to the column at a loading of not greater than 20 mg per ml of resin. The column is eluted with 10-20 column volumes of a gradient of sodium chloride in the range of 0-0.5 M dissolved in the same buffer in which the column was equilibrated. Sodium chloride or other appropriate salt is added to increase the conductivity and thereby elute the GM-CSF. Fractions are combined based on sodium dodecyl sulfate- polyacryla ide gel electrophoresis (SDS-PAGE) and chromatographed in Stage III. Stage III. Dye Affinity Chromatography
The combined fractions from the anion exchange (e.g. QAE) column are diluted with deionized water to a conductivity of 5-10 mS and loaded onto a dye-ligand affinity column, e.g. Procion Red HE3B attached to an agarose support, which had been previously equilibrated with 2-3 column volumes of appropriate pH 7.5 buffer, e.g. 20 mM Tris-HCl. The amount of protein loaded onto the column should not exceed 10 mg per ml of gel.
The column is washed with 3-4 column volumes of the equilibration buffer. Elution is performed with between 5 and 15 volumes of a gradient of sodium chloride or other appropriate salt from 0 to 0.75 M dissolved in the equilibration buffer. The fractions to be employed in Stage IV are combined on the basis of SDS-PAGE.
Stage IV. Concentration By Ultrafilitration and/or Ammonium Sulfate Precipitation
If the protein concentration of the combined fractions from the previous stage is less than 1.0 mg/ml, the solution is concentrated by ultrafiltration employing a 3,000-5,000 molecular weight cut-off membrane. The final protein concentration should be 1.0 mg/ml or greater. Ammonium sulfate is added to a final concentration of 60-70%. The precipitate is collected by centrifugation and then washed once with 20 mM Tris-HCl, pH 7.5, or other suitable buffer containing the same concentration of ammonium sulfate as employed for precipitation. The precipitate is collected by centrifugation and dissolved in the same buffer.
Stage V. Gel Filtration Chromatography The redissolved ammonium sulfate precipitate may be clarified by centrifugation, if required. The solution is filtered through a 0.2 u filter and charged onto a gel filtration column such as a Sephadex G-100 column equilibrated with an appropriate buffer at pH 7.5, e.g. 20 mM Tris-HCl. The amount of protein loaded onto the column should not exceed 3 mg per ml of gel. The column is eluted with the same buffer. Fractions for stage VI are combined based on SDS-PAGE.
Stage VI. Reversed-Phase Column Chromatography
The combined fractions from the gel filtration are passed through a 0.2 μ filter and applied to a reversed-phase column, e.g., FPLC or HPLC columns. The column is equilibrated with an acidic solution such as 0.1% trifluoroacetic acid (TFA) and elution is performed with a gradient of 0-100% of an inert solvent such as acetonitrile dissolved in the acidic solution. Fractions are combined based on SDS-PAGE. The solution is lyophilized and the dried powder is dissolved in a buffer solution at pH 7.2, e.g., 20 mM sodium phosphate.
Stage VII. Dialysis of the Purified GM-CSF
The solution from Stage VI is dialyzed against a buffer at pH 7.2, e.g., 20 mM sodium phosphate. Two changes of buffer are performed with a minimum of 4-5 hours between changes. If required, the dialyzed solution is concentrated by ultrafiltration using a 3,000-5,000 molecular weight cut-off membrane to a protein concentration of at least 1.0 mg/ml. The solution of purified GM-CSF is passed through a 0.2 μ filter and stored frozen at about -20°C or below. Following is a specific example of GM-CSF purification. Roman numerals correspond to some of the Stages of the general description above.
Stage II. QAE Column Chromatography
The neutralized protein extract was adjusted to pH 7.5 with sodium hydroxide. The extract was then diluted approximately 2-fold with cold deionized water to reach a final conductivity of 8 S. A 6.5 liter column (BIOPROCESS 252/15, manufactured by Pharmacia) was equilibrated with 3 column volumes of 20 mM Tris.HCl, pH 7.5. Extract (50 liters) was applied to the column at a loading of 8.6 mg protein per ml of resin. The column was eluted at a flow of 400 ml/ in, first with 30 liters of equilibration buffer, and then with 70 liters of a linear gradient established between 35 liters of 20 mM Tris.HCl, pH 7.5 and 35 liters of 20 mM Tris.HCl, pH 7.5 containing 0.4 M NaCl. Fractions (4-5 liters) were combined based on gel electrophoresis (SDS-PAGE) and the pooled protein (2.0 grams) was chromatographed in Stage III.
Stage III. Dye Affinity Chromatography
The combined fractions from the QAE column were concentrated by ultrafiltration (3,000-5,000 molecular weight cut-off membrane) to 1 liter, and then diluted 5- fold with cold deionized water to a conductivity of 8 mS. This pool (5 liters) was then loaded at a ratio of 6.7 mg/ml onto a 300 ml Matrex Gel Red A column which had previously been equilibrated with three column volumes of 20 mM Tris.HCl, pH 7.5. The column was then washed with 600 ml of equilibrating buffer, and the 2.0 gram load was eluted using a linear gradient established between 1.5 liters of 20 mM Tris.HCl, pH 7.5 and 1.5 liters of 20 mM Tris.HCl, pH 7.5 containing 0.75 M NaCl. The fractions were combined based on gel electrophoresis, and the fractions (1.5 liters containing 1.12 gram of protein) were concentrated by ultrafiltration in Stage IV.
Stage IV. Concentration of Dye Ligand Eluate By Ultrafiltration
The 1.5 liter eluate of the dye ligand chromatography contained 0.75 mg/ml. Ultrafiltration of this pool was performed in an Amicon high-output stainless steel stirred cell (Model 2000). A YM-5 membrane (150 mm) (Amicon) was used with a flow rate of 10 ml/min., 80 PSI and 4°C. The sample was concentrated to a volume of 75 ml and 10-15 mg/ml. Following the ultrafiltration, the sample was filtered through a .22 μ cellulose nitrate membrane. Ammonium sulfate was added to a final concentration of 60% (390 mg/ml). The solution was held at 4°C without mixing for 2 hours, and then centrifuged at 4,000 rpm for 45 min at 4°C. The precipitate was collected, and resuspended in one liter of 20 mM Tris.HCl, pH 7.5 containing 60% saturated ammonium sulfate at 4°C. The sample was centrifuged at 4,000 rpm for 45 min at 4°C.
Stage V. Sephadex G-100 Chromatography
The redissolved ammonium sulfate pellet was charged onto a 2 liter column at a flow rate of 2 ml/min. A loading ratio of 0.5 mg of protein per ml of resin was used and the sample was eluted with the equilibrating buffer, 20 mM Tris.HCl, pH 7.5. Fractions were combined based on gel electrophoresis (SDS-PAGE), and the 300 ml volume containing 350 mg of protein was frozen at -20°C until it was applied to the reversed- phase column. Stage VI. Reversed-Phase Column Chromatography
The combined fractions of the gel filtration column were passed through a 0.2 μ filter and applied onto a 20 ml PRORPC-C2/C8 (Pharmacia) column at a flow rate of 2.5 ml/min. The column had previously been equilibrated with solvent containing 0.1% TFA in water. Four identical chromatographies (100 mg per run) were performed. Sample was eluted using a linear gradient between 35% acetonitrile, 0.1% TFA and 100% acetonitrile, 0.1% TFA over a 125 min. time period. Fractions were combined based on SDS-PAGE. The solution was lyophilized, and the dried powder was dissolved in 20 mM sodium phosphate, pH 7.2.
Stage VII. Dialysis of The Purified GM-CSF
The pool from the reversed-phase column was dialysed against three changes of 20 mM sodium phosphate buffer, pH 7.2. The solution was then sterile-filtered through a 0.2 μ filter and frozen at -20°C.

Claims

Claims :
1. A method of purifying granulocyte-macrophage -colony-stimulating factor (GM-CSF) from a culture medium of a microorganism obtained by a recombinant DNA technique and capable of producing the GM-CSF, comprising the sequential steps of removal of proteases, removal of hydrophobic impurities, separation of high and low molecular weight impurities, and separation of related proteins.
2. A method as claimed in claim 1 wherein the GM- CSF is human GM-CSF.
3. A method as claimed in claim 2 wherein the GM- CSF is recombinant human GM-CSF.
4. A method as claimed in any of claim 1 to 3 wherein the proteases are removed by anion-exchange chromatography, the hydrophobic impurities are removed by dye-ligand affinity chromatography, the high and low- molecular weight impurities are removed by gel-filtration chromatography, and GM-CSF-related proteins are removed by reversed phase chromatography.
5. A method as claimed in claim 4 wherein the anion exchange resin is a quaternary aminoethyl resin.
6. A method as claimed in claim 4 or claim 5 wherein the dye-ligand affinity column comprises a triazinyl dye on an agarose support.
7. A method as claimed in any of claims 4 to 6 wherein the gel-filtration column is a cross-linked dextran-based gel having a cut-off range of from about 1,000 to about 200,000 for proteins.
8. A method as claimed in any of claims 4 to 7 wherein the reversed phase chromatography is fast protein liquid chromatography using a C4 or C8 column.
9. A method as claimed in any of claims 4 to 8 comprising removal of protease with a quaternary aminoethyl resin, removal of hydrophobic impurities with a column comprising a triazinyl dye on an agarose support, removal of high and low molecular weight impurities with a cross-linked dextran-based gel having a cut-off range of from about 1,000 to about 200,000 for proteins, and removal of related proteins by fast protein liquid chromatography using a C4 or C8 column.
EP88906521A 1987-07-16 1988-07-13 Purification of gm-csf Pending EP0368904A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7441087A 1987-07-16 1987-07-16
US74410 1987-07-16

Publications (1)

Publication Number Publication Date
EP0368904A1 true EP0368904A1 (en) 1990-05-23

Family

ID=22119421

Family Applications (2)

Application Number Title Priority Date Filing Date
EP88906521A Pending EP0368904A1 (en) 1987-07-16 1988-07-13 Purification of gm-csf
EP88306421A Expired - Lifetime EP0299746B1 (en) 1987-07-16 1988-07-13 Purification of gm-csf

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP88306421A Expired - Lifetime EP0299746B1 (en) 1987-07-16 1988-07-13 Purification of gm-csf

Country Status (16)

Country Link
EP (2) EP0368904A1 (en)
JP (1) JPH0779709B2 (en)
KR (1) KR930007430B1 (en)
AT (1) ATE79884T1 (en)
AU (1) AU632460B2 (en)
DE (1) DE3874034T2 (en)
DK (1) DK11290D0 (en)
ES (1) ES2034239T3 (en)
GR (1) GR3006267T3 (en)
HK (1) HK182095A (en)
IE (1) IE63323B1 (en)
IL (1) IL87123A0 (en)
MY (1) MY103539A (en)
NZ (1) NZ225410A (en)
WO (1) WO1989000579A1 (en)
ZA (1) ZA885100B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503897A (en) * 1988-04-21 1991-08-29 メドベット・サイエンス・プロプライアテリー・リミテッド Human GM-CSF variants
KR100406019B1 (en) * 1998-09-30 2004-03-20 주식회사유한양행 Regeneration method of encapsulated human granulocyte leukocyte colony stimulating factor using gel filtration column chromatography
US7598356B2 (en) * 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
KR101921552B1 (en) 2014-03-10 2018-11-23 리히터 게데온 닐트. Immunoglobulin purification using pre-cleaning steps

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617296A (en) * 1984-06-19 1986-01-13 イミユネツクス、コ−ポレ−シヨン Purification, cloning and characterization of gene of interleukin 1
EP0188479B1 (en) * 1984-07-06 1991-09-11 Sandoz Ag Lymphokine production and purification
JPS61124392A (en) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd Purification of physiologically active substance produced by gene recombinant
EP0215126B1 (en) * 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
JPS62153752A (en) * 1985-12-27 1987-07-08 Showa Denko Kk Adsorber carrier for chromatography

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8900579A1 *

Also Published As

Publication number Publication date
DK11290A (en) 1990-01-15
GR3006267T3 (en) 1993-06-21
HK182095A (en) 1995-12-08
AU632460B2 (en) 1993-01-07
DK11290D0 (en) 1990-01-15
ATE79884T1 (en) 1992-09-15
DE3874034D1 (en) 1992-10-01
ZA885100B (en) 1989-01-16
KR930007430B1 (en) 1993-08-10
JPH02502640A (en) 1990-08-23
NZ225410A (en) 1990-09-26
EP0299746B1 (en) 1992-08-26
DE3874034T2 (en) 1993-01-07
WO1989000579A1 (en) 1989-01-26
EP0299746A1 (en) 1989-01-18
IE63323B1 (en) 1995-04-05
KR890701617A (en) 1989-12-21
JPH0779709B2 (en) 1995-08-30
MY103539A (en) 1993-07-31
ES2034239T3 (en) 1993-04-01
IL87123A0 (en) 1988-12-30
AU2085188A (en) 1989-02-13
IE882146L (en) 1989-01-16

Similar Documents

Publication Publication Date Title
van DAMME et al. Purification of granulocyte chemotactic peptide/interleukin‐8 reveals N‐terminal sequence heterogeneity similar to that of β‐thromboglobulin
AU584032B2 (en) Method for the purification of erythroppietin and erythropoietin compositions
Nomura et al. Purification and characterization of human granulocyte colony‐stimulating factor (G‐CSF).
Yoshimura et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.
KR927002375A (en) Megakaryocyte forming factor
KR960000394B1 (en) Leucoyte decreasing cure
EP0165654B1 (en) Purified interleukin 1
EP0479071B1 (en) Polypeptide
HU204537B (en) Process for purifying gm-csf
KR20040071212A (en) Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
JPS61124392A (en) Purification of physiologically active substance produced by gene recombinant
US5149544A (en) Method of inhibiting progenitor cell proliferation
EP0276551A1 (en) Colony-stimulating factor and method for preparation thereof
EP0299782B1 (en) Expression vectors for the production of human granulocyte-macrophage colony stimulation factor in a mammalian cell host(18.05.92)
US5451662A (en) Method of purifying protein
US5391706A (en) Purification of GM-CSF
AU632460B2 (en) Purification of gm-csf
CA2128215C (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
US6087123A (en) Metal-containing ribonucleotide polypeptides
EP0413818B1 (en) Process for producing a human neutrophil chemotactic factor polypeptide
RU2278870C2 (en) Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
EP0210588B1 (en) Antitumor polypeptide and a method of preparing the same
Potter et al. Separation and purification of lymphocyte chemotactic factor (LCF) and interleukin 2 produced by human peripheral blood mononuclear cells
KR0160934B1 (en) Process for the purification of recombinant human granulocyte-colony stimulating factor in the form of inclusion body from yeast
JPH022390A (en) Novel stimulation factor for human granulocyte macrophage colony

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19891218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 88306421.4/0299746 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 06.08.90.